No emergence of resistance mutations in COVID‐19 patients receiving nirmatrelvir/ritonavir
Authors:
- Cristina VeintimillaCVCristina Veintimilla
- Laura Pérez‐LagoLPLaura Pérez‐Lago
- the Gregorio Marañón Microbiology‐ID COVID 19 Study GroupTGthe Gregorio Marañón Microbiology‐ID COVID 19 Study Group
- 27 December 2023
- journal article
- letter
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (1) , e29337
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2Med, 2023
- A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutationsPLOS Pathogens, 2023
- Nirmatrelvir Resistance—de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure—a Case ReportClinical Infectious Diseases, 2023
- Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to NirmatrelvirACS Central Science, 2023
- Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving SotrovimabAntimicrobial Agents and Chemotherapy, 2023
- The effect of nirmatrelvir‐ritonavir on viral clearance and length of hospital stay in patients infected with SARS‐CoV‐2 omicron variantsInfluenza and Other Respiratory Viruses, 2023
- Multiple pathways for SARS-CoV-2 resistance to nirmatrelvirNature, 2022
- Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomesBiochemical and Biophysical Research Communications, 2022
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19New England Journal of Medicine, 2022